AZN-OLD
AstraZeneca PLC
AstraZeneca PLC historical holders
total: 7
Sanders Capital AstraZeneca PLC transactions over time
- Total transactions:
- 11
- New positions:
- 1
- Sold out:
- 1
- Added:
- 6
- Reduced:
- 3
- Held since:
- 2023 Q3
- Held for:
- 10 quarters
- Latest activity:
- 2026 Q1
Lewis Sanders has been an institutional investor in AstraZeneca PLC (AZN-OLD) since 2023 Q3. According to 2026 Q2 report, Lewis Sanders doesn't hold any shares. The fund/company first acquired AZN-OLD in 2023 Q3, initially purchasing about 10.56M shares. Since the initial investment, Sanders Capital has made 10 more transactions in this position.
When did Lewis Sanders exit their AZN-OLD position?
Lewis Sanders no longer holds AstraZeneca PLC (AZN-OLD). They sold off their entire position in 2026 Q1, closing out an investment that began in 2023 Q3.
When did Lewis Sanders first invest in AZN-OLD?
Lewis Sanders first invested in AstraZeneca PLC (AZN-OLD) in 2023 Q3 at the reported quarter-end price of $67.72 per share, acquiring 10,561,101 shares in their initial purchase.
What is Lewis Sanders's average cost basis for AZN-OLD?
Based on historical transaction data, Lewis Sanders's estimated cost basis for AstraZeneca PLC (AZN-OLD) is approximately $67.82 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $67.82
- Weighted AVG sell price:
- $90.54
AZN-OLD transactions history by Sanders Capital
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$91.93
|
|
-100% (-14,139,408)
|
-1.5%
|
|
2025 Q4
|
1.50%
|
14,139,408
|
$91.93
|
$1,299,835,777
|
+0.57% (+80,726)
|
+0.01%
|
|
2025 Q3
|
1.33%
|
14,058,682
|
$76.72
|
$1,078,582,083
|
-3.22% (-468,180)
|
-0.05%
|
|
2025 Q2
|
1.36%
|
14,526,862
|
$69.88
|
$1,015,137,117
|
-3.60% (-542,124)
|
-0.06%
|
|
2025 Q1
|
1.66%
|
15,068,986
|
$73.50
|
$1,107,570,471
|
-0.78% (-117,706)
|
-0.01%
|
|
2024 Q4
|
1.45%
|
15,186,692
|
$65.52
|
$995,032,060
|
+1.42% (+212,301)
|
+0.02%
|
|
2024 Q3
|
1.69%
|
14,974,391
|
$77.91
|
$1,166,654,803
|
+0.20% (+29,149)
|
+0%
|
|
2024 Q2
|
1.79%
|
14,945,242
|
$77.99
|
$1,165,579,424
|
+0.85% (+126,259)
|
+0.02%
|
|
2024 Q1
|
1.68%
|
14,818,983
|
$67.75
|
$1,003,986,098
|
+0.92% (+134,917)
|
+0.02%
|
|
2023 Q4
|
1.83%
|
14,684,066
|
$67.35
|
$988,971,845
|
+39.04% (+4,122,965)
|
+0.51%
|
|
2023 Q3
|
1.51%
|
$67.72
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.